Peng Bo

Prof. Peng Bo

Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in EBioMedicine
Verified
Journal Article
Open access
WHWeiren Huang
Weiren Huang
LYLei Yu
Lei Yu
DWDonghua Wen
Donghua Wen
DWDong Wei
Dong Wei
YSYangyang Sun
Yangyang Sun
JWJin Wang
Jin Wang
Real-time reverse transcription-PCR (rRT-PCR) has been the most effective and widely implemented diagnostic technology since the beginning of the COVID-19 pandemic. However, fuzzy rRT-PCR readouts with high Ct values are frequently encountered, resulting in uncertainty in diagnosis. A Specific Enhancer for PCR-amplified Nucleic Acid (SENA) was developed based on the Cas12a trans-cleavage activity, which is specifically triggered by the rRT-PCR amplicons of the SARS-CoV-2 Orf1ab (O) and N fragments. SENA was first characterized to determine its sensitivity and specificity, using a systematic titration experiment with pure SARS-CoV-2 RNA standards, and was then verified in several hospitals, employing a couple of commercial rRT-PCR kits and testing various clinical specimens under different scenarios. The ratio (10 min/5 min) of fluorescence change (FC) with mixed SENA reaction (mix-FCratio) was defined for quantitative analysis of target O and N genes, and the Limit of Detection (LoD) of mix-FCratio with 95% confidence interval was 1.2≤1.6≤2.1. Totally, 295 clinical specimens were analyzed, among which 21 uncertain rRT-PCR cases as well as 4 false negative and 2 false positive samples were characterized by SENA and further verified by next-generation sequencing (NGS). The cut-off values for mix-FCratio were determined as 1.145 for positive and 1.068 for negative. SENA increases both the sensitivity and the specificity of rRT-PCR, solving the uncertainty problem in COVID-19 diagnosis and thus providing a simple and low-cost companion diagnosis for combating the pandemic. Detailed funding information is available at the end of the manuscript.

6 June 2014 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
SFShisong Fang
Shisong Fang
KZKaining Zhang
Kaining Zhang
Ting WangTing Wang
Ting Wang
XWXin Wang
Xin Wang
XLXing Lu
Xing Lu
JCJinquan Cheng
Jinquan Cheng

12 August 2024 in Viruses
Verified
Journal Article
Open access
PDF file
JQJing Qu
Jing Qu
XZXiaomin Zhang
Xiaomin Zhang
KLKun Liu
Kun Liu
YLYou Li
You Li
TWTing Wang
Ting Wang
Peng BoPeng Bo
Peng Bo
Accurate and early diagnosis of monkeypox virus (MPXV) is crucial for controlling epidemics and treating affected individuals promptly. This study aimed to assess the analytical and clinical performance of the MolecisionTM Monkeypox Virus qPCR Assay, Biorain Monkeypox Virus ddPCR Assay, and MAGLUMI® Monkeypox Virus Ag (chemiluminescence immunoassay, CLIA) Assay. Additionally, it aimed to compare the clinical application of antigen and nucleic acid assays to offer insights into using commercial monkeypox assay kits. Specimens from 117 clinical patients, serial diluted virus cell culture supernatant, and artificially created positive samples were tested to evaluate the performance of these assay kits for MPXV diagnostics. The Biorain Monkeypox Virus ddPCR Assay had a limit of detection (LoD) of 3.89 CCID50/mL, while the MolecisionTM Monkeypox Virus qPCR Assay had an LoD of 15.55 CCID50/mL. The MAGLUMI® Monkeypox Virus Ag (CLIA) Assay had an LoD of 0.500 pg/mL. The accuracy of the MolecisionTM Monkeypox Virus qPCR Assay was comparable to the Biorain Monkeypox Virus ddPCR Assay, and the MAGLUMI® Monkeypox Virus Ag (CLIA) Assay demonstrated high sensitivity. The specificity of all three MPXV diagnostic assays for clinical specimens with potential cross-reacting substances was 100%. In conclusion, this study provides valuable insights into the clinical application of monkeypox assays, supporting efforts to mitigate and control the spread of monkeypox.

23 February 2021 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
SFShisong Fang
Shisong Fang
LZLin Zhang
Lin Zhang
YLYingzhi Liu
Yingzhi Liu
WXWenye Xu
Wenye Xu
WWWeihua Wu
Weihua Wu
JXJunjie Xia
Junjie Xia
Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, causing significant mortality. There is a mechanistic relationship between intracellular coronavirus replication and deregulated autophagosome–lysosome system. We performed transcriptome analysis of peripheral blood mononuclear cells (PBMCs) from COVID-19 patients and identified the aberrant upregulation of genes in the lysosome pathway. We further determined the capability of two circulating markers, namely microtubule-associated proteins 1A/1B light chain 3B (LC3B) and (p62/SQSTM1) p62, both of which depend on lysosome for degradation, in predicting the emergence of moderate-to-severe disease in COVID-19 patients requiring hospitalization for supplemental oxygen therapy. Logistic regression analyses showed that LC3B was associated with moderate-to-severe COVID-19, independent of age, sex and clinical risk score. A decrease in LC3B concentration <5.5 ng/ml increased the risk of oxygen and ventilatory requirement (adjusted odds ratio: 4.6; 95% CI: 1.1–22.0; P = 0.04). Serum concentrations of p62 in the moderate-to-severe group were significantly lower in patients aged 50 or below. In conclusion, lysosome function is deregulated in PBMCs isolated from COVID-19 patients, and the related biomarker LC3B may serve as a novel tool for stratifying patients with moderate-to-severe COVID-19 from those with asymptomatic or mild disease. COVID-19 patients with a decrease in LC3B concentration <5.5 ng/ml will require early hospital admission for supplemental oxygen therapy and other respiratory support.

1 January 2025 in China CDC Weekly
Verified
Journal Article
Open access
PDF file
WGWenxiao Gong
Wenxiao Gong
DWDongli Wang
Dongli Wang
QCQianying Chen
Qianying Chen
SZShuting Zhong
Shuting Zhong
XSXiaolu Shi
Xiaolu Shi
Peng BoPeng Bo
Peng Bo
What is already known about this topic? The circulating strain in the recent Chikungunya fever outbreak in Guangdong Province belongs to the East/Central/South African (ECSA) genotype. However, the specific mutations in the viral genome remained unclear. What is added by this report? This study conducted whole-genome sequencing of viral sequences from clinical samples. The results confirmed that the epidemic strain belongs to the Middle African Lineage (MAL) within the ECSA genotype, not the Indian Ocean Lineage (IOL). Further analysis of nucleotide mutations revealed several adaptive mutations compared with the S27 genomic sequence (NC_004162), such as E1-A226V, E2-L210Q, and E2-I211T. What are the implications for public health practice? Based on previous genomic surveillance and pathogen studies, mutations like E1-A226V, E2-L210Q, and E2-I211T were generally considered characteristic of IOL within the ECSA genotype and are known to enhance viral replication and transmission efficiency in Aedes albopictus mosquitoes. This study identifies the circulating strain in Guangdong belongs to MAL, which is phylogenetically distinct from IOL, yet also carries these mutations. This suggests these may represent adaptive changes in the MAL strain to a new mosquito host. In Guangdong Province, Ae. albopictus is the predominant mosquito species, while the distribution of Ae. aegypti is relatively limited. The ecological predominance of Ae. albopictus likely serves as a key contributing factor facilitating the rapid importation and subsequent widespread dissemination of the current epidemic strain.

1 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
DZDingmei Zhang
Dingmei Zhang
JZjiayi zhong
jiayi zhong
HXHusheng Xiong
Husheng Xiong
YLYufen Li
Yufen Li
TGTong Guo
Tong Guo
YMYu Ma
Yu Ma
This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study and recruited the test-positive cases and test-negative controls in the outbreak caused by Omicron BA.2 in April 2022 in Guangzhou, China. All the participants were 3 years and older. The vaccination status between the case group and the control group was compared in the vaccinated and all participants, respectively, to estimate the immune protection of inactivated COVID-19 vaccines. After adjusting for sex and age, compared with a mere single dose, full vaccination of inactivated COVID-19 vaccines (OR = 0.191, 95% CI: 0.050 to 0.727) and booster vaccination (OR = 0.091, 95% CI: 0.011 to 0.727) had a more superior protective effect. Compared with one dose, the second dose was more effective in males (OR = 0.090), as well as two doses (OR = 0.089) and three doses (OR = 0.090) among individuals aged 18–59. Whereas, when compared with the unvaccinated, one dose (OR = 7.715, 95% CI: 1.904 to 31.254) and three doses (OR = 2.055, 95% CI: 1.162 to 3.635) could contribute to the increased risk of Omicron infection after adjusting for sex and age. Meanwhile, by contrast with unvaccinated individuals, the result of increased risk was also manifested in the first dose in males (OR = 12.400) and one dose (OR = 21.500), two doses (OR = 1.890), and a booster dose (OR = 1.945) in people aged 18–59. In conclusion, the protective effect of full and booster vaccination with inactivated COVID-19 vaccines exceeded the incomplete vaccination, of which three doses were more effective. Nevertheless, vaccination may increase the risk of Omicron infection compared with unvaccinated people. This may result from the transmission traits of BA.2, the particularity and stronger protection awareness of the unvaccinated population, as well as the ADE effect induced by the decrease of antibody titers after a long time of vaccination. It is crucial to explore this issue in depth for the formulation of future COVID-19 vaccination strategies.